Cocrystal Pharma, Inc.

126 articles about Cocrystal Pharma, Inc.

• Cocrystal Pharma Provides Update on Influenza A Program

  10/19/2020

  – New in vitro data demonstrating antiviral activity with lead compound CC-42344 against Xofluza (baloxavir)-resistant H1N1 strain – – Company continues to advance IND-enabling studies for Phase 1 clinical study in 2021 –

• Cocrystal Pharma Announces Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions

  10/2/2020

  Cocrystal Pharma, Inc.  (NASDAQ: COCP) The following is being released by Cocrystal Pharma, Inc. pursuant to an order of the United States District Court, District of New Jersey, regarding Agreement of Settlement. UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY TRENT NICHOLS and SHARON NICHOLS, derivatively on behalf of COCRYSTAL PHARMA, INC. F/K/A BIOZONE PHARMACEUTICALS, INC.,                 Plaintiffs,                 vs. ELLI

• Cocrystal Pharma to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

  9/8/2020

  – Live video webcast with Chairman and CEO, Dr. Gary Wilcox, on Monday, September 14 th at 3:30 PM EDT –

• Cocrystal Pharma Announces $10.0 Million Bought Deal Offering

  8/26/2020

  Cocrystal Pharma, Inc.   (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, announced today that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 9,523,810 shares of common stock of the Company, at a price to the public of $1.05 per share, less

• Cocrystal Pharma Reports Second Quarter 2020 Financial Results and Provides Updates on Antiviral Programs

  8/6/2020

  – COVID-19 program in preclinical development; Discussions with potential strategic partners ongoing – – Merck collaboration to discover and develop influenza A/B antiviral agents progresses –

• Cocrystal Pharma Announces the Publication by Collaborators of Positive Data Demonstrating Potent In Vitro Inhibition Against Coronavirus in Science Translational Medicine Journal

  8/4/2020

  – Cocrystal has two exclusive licenses for the coronavirus protease inhibitors described in the publication – – Cocrystal is currently further conducting preclinical studies of these coronavirus protease inhibitors (3CL) – BOTHELL, WA, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc.   (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced the publication of preclinical an

• Cocrystal Pharma Reports First Quarter 2020 Financial Results and Provides Updates on Antiviral Programs

  5/14/2020

  Company has sufficient capital to advance pipeline and fund operations through 2021

• Cocrystal Pharma Provides COVID-19 Impact Update on Development Programs

  5/11/2020

  – Company reprioritizes activities to accelerate development and provides next steps for advancing preclinical COVID-19 Coronavirus program – – Discussions ongoing with potential strategic partners for COVID-19 Coronavirus program – – Collaboration with Merck to discover and develop certain proprietary influenza A/B antiviral agents remains ongoing – – Supply chain delay in fully owned influenza A virus program – – Norovirus program on track to complete proof-of-concept animal st

• Cocrystal Pharma Expands Exclusive License Agreement with Kansas State University Research Foundation to New Coronavirus Antiviral Compounds with Novel Mechanism of Action

  4/22/2020

  Small molecule therapeutic inhibitors against coronaviruses included in agreement have demonstrated strong proof-of-concept and excellent efficacy data inMERS-CoV animal models

• Cocrystal Pharma Announces Appointment of Nobel Laureate and Scientific Advisor, Roger D. Kornberg, Ph.D., to Board of Directors

  4/20/2020

  Cocrystal Pharma, Inc .  (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, announced today the appointment of Dr. Roger Kornberg to its Board of Directors

• Cocrystal Pharma to Present at the April 2020 Virtual Investor Summit

  4/15/2020

  – Presentation with live audio webcast on Wednesday, April 22 at 11:00 AM ET, immediately followed by an interactive Q&A session –

• Cocrystal Pharma Reports 2019 Financial Results and Outlines Expected Value-Driving Milestones for 2020

  3/30/2020

  Advancing preclinical COVID-19 Coronavirus program leveraging patent rights recently acquired from Kansas State University Research Foundation (“KSURF”)

• Cocrystal Pharma Announces Closing of $6.8 Million Registered Direct Offering Priced At-the-Market

  3/11/2020

  COCRYSTAL PHARMA, INC.  announced registered direct offering with several institutional investors for 5,037,038 shares of its common stock at a purchase price of $1.35 per share, priced at-the-market under Nasdaq rules.

• Cocrystal Pharma Announces $6.8 Million Registered Direct Offering Priced At-the-Market

  3/9/2020

  COCRYSTAL PHARMA, INC. announced that it has entered into definitive agreements with several institutional investors for the purchase of 5,037,038 shares of its common stock at a price of $1.35 per share, for aggregate gross proceeds of approximately $6.8 million, in a registered direct offering priced at-the-market under Nasdaq rules.

• Cocrystal Pharma Announces Plans to Advance Coronavirus Program

  3/6/2020

  Company has immediately initiated Coronavirus program Leveraging patent rights recently acquired from Kansas State University Research Foundation (“KSURF”) Strong financial position bolsters Company’s ongoing research and development efforts

• Cocrystal Pharma Announces Closing of $11.0 Million Registered Direct Offering Priced At-the-Market

  2/28/2020

  COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, announced today the closing of its previously announced registered direct offering with several institutional investors for 8,461,540 shares of its common stock at a purchase price of $1.30 per share, priced at-the-market under Nasdaq rules.

• Cocrystal Pharma Announces $11.0 Million Registered Direct Offering Priced At-the-Market

  2/27/2020

  COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced that it has entered into definitive agreements with several institutional investors for the purchase of 8,461,540 shares of its common stock at a price of $1.30 per share, for aggregate gross proceeds of approximately $11.0 million, in a registered direct offering priced at-the-market under Nasdaq rules

• Cocrystal Pharma, Inc. Announces License Agreement with Kansas State University Research Foundation for Norovirus and Coronavirus Antiviral Compounds

  2/24/2020

  COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced that it has entered into a license agreement with Kansas State University Research Foundation (“KSURF”) to further develop certain proprietary broad-spectrum antiviral compounds for the treatment of Norovirus and Coronavirus infections. 

• Cocrystal Pharma Inc.’s Structure-Based Technology has Demonstrated Broad Utility in Development of Antivirals

  2/13/2020

  –   Positive preclinical and clinical data obtained to date in hepatitis C, influenza and norovirus programs bolster confidence in potential of our platform to address additional viral diseases, including coronavirus respiratory infections – BOTHELL, WA, Feb. 13, 2020 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics using its proprietary structure-based

• Cocrystal Pharma Inc. to Present at Noble Capital Markets’ 16th Annual Investor Conference

  2/11/2020

  – Presentation on Tuesday, February 18 th at 11:30 AM ET – BOTHELL, WA, Feb. 11, 2020 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”) , a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced that Dr. Gary Wilcox, Chairman and Chief Executive Officer of Cocrystal, will present at NobleCon16 - Noble Capital Markets’ 16th Annual Investor Conference on Tuesday, February 18, 2020 at 11:30 a.m. ET i